Barclays PLC set a €105.00 ($123.53) price objective on Bayer AG (FRA:BAYN) in a report issued on Friday. The firm currently has a sell rating on the healthcare company’s stock.

A number of other brokerages have also recently issued reports on BAYN. Citigroup Inc. set a €130.00 ($152.94) price target on Bayer AG and gave the stock a buy rating in a research report on Thursday, October 5th. UBS AG set a €125.00 ($147.06) price objective on Bayer AG and gave the company a buy rating in a research report on Monday, November 6th. Independent Research GmbH set a €120.00 ($141.18) price objective on Bayer AG and gave the company a neutral rating in a research report on Thursday, July 27th. Deutsche Bank AG set a €124.00 ($145.88) price objective on Bayer AG and gave the company a buy rating in a research report on Monday, August 28th. Finally, Kepler Capital Markets set a €102.00 ($120.00) price objective on Bayer AG and gave the company a neutral rating in a research report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of Buy and an average price target of €122.43 ($144.03).

Shares of Bayer AG (FRA BAYN) opened at €108.65 ($127.82) on Friday. Bayer AG has a 1 year low of €86.06 ($101.25) and a 1 year high of €123.82 ($145.67).

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://theolympiareport.com/2017/11/21/barclays-plc-analysts-give-bayer-ag-bayn-a-105-00-price-target.html.

About Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womenÂ’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer AG (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with Analyst Ratings Network's FREE daily email newsletter.